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Background:Testosterone (T) is mainly excreted in the urine as testosterone glucuronide
(TG).This glucuronidation is partly dependent on the UGT2B17 genotype, andTG excretion
is therefore lower in men having the UGT2B17 deletion. However, the possible influence
of UGT2B17 genotype on serum T during androgen therapy is unknown. We retrospec-
tively investigated the possible association between the UGT2B17 gene polymorphism
and serumT levels in hypogonadal men duringTestosterone undecanoate (TU) substitution
therapy.
Subjects and Methods:Two hundred and seven patients treated withTU (Nebido®) were
genotyped by quantitative polymerase chain reaction for the UGT2B17 deletion polymor-
phism. All were given 1000 mg TU per injection at 0, 6, and 18 weeks. Blood samples
were taken 2 and 6 weeks after the first and second injection, prior to the third injection,
and after 2–3 years of treatment. We analyzed for the levels of T, luteinizing hormone (LH),
sex-hormone-binding globulin, estradiol, prostate specific antigen, hematocrit, hemoglobin,
and total cholesterol.
Results: The UGT2B17 genotype frequency was: ins/ins: 42%, ins/del: 44%, and del/del:
14%. During the initial 18 weeks ofTU treatment, large intra- and inter-individual variations
in serum T levels were observed. Large peaks in T levels, ranging from 6.7 to 69.5 nmol/l,
were noted 2 weeks after injections, regardless of the genotype. T levels did not differ
between the three genotypes prior to the third injection, but the del/del group had sig-
nificantly lower levels of LH. At follow-up after 2–3 years, the injection interval or daily T
dosage was not dependent on the UGT2B17 genotype.
Conclusion: In conclusion, we found large intra- and inter-individual variations in serum
T during standard TU treatment regimen in hypogonadal men. Only subtle differences in
serumT and LH were noted according to UGT2B17 genotype, which however suggest that
the UGT2B17 genotype exert modest influence on the pharmacokinetic profile of T after
TU treatment.
Keywords: UGT2B17, testosterone, testosterone undecanoate, hypogonadism, testosterone treatment
INTRODUCTION
The male sexual hormone Testosterone (T) became available for
clinical use approximately 70 years ago (1). Since then, the increase
in the clinical use of T in treatment of men with androgen defi-
ciency, but also its illicit use as a performance enhancer in sports
has resulted in increased research activity on factors influencing
the metabolism and excretion of T. A commonly used method to
screen for possible illicit intake of T is based on the urinary ratio
of T-glucuronide (TG) and epitestosterone glucuronide, often
referred to as the T/E-ratio.
In 2006 a novel discovery was made when Jakobsson and
co-workers demonstrated that a common polymorphism in the
UGT2B17 gene influenced the excretion of T in the urine (2).
The UGT2B17 gene encodes an enzyme that belongs to a large
family of UDP-glucuronosyltransferases that catalyzes the trans-
fer of glucuronosyl group from uridine 5′-diphospho-glucuronic
acid to a large variety of substrates including steroid hormones
[for review, see Ref. (3)]. This glucuronidation results in more
polar and hydrophilic steroids, and hereby facilitates their elimi-
nation through bile and urine. The UGT2B17 polymorphism is
a copy number variation, occurring in populations with variable
frequency. The homozygous deletion is much more common in
the Korean (67%) and Chinese (77%) population than, e.g., the
Swedish (9%) and Danish (9%) populations (2, 4, 5). Men carry-
ing one or two alleles of the UGT2B17 gene excrete significantly
greater (8 and 13 times, respectively) amounts of TG in the urine
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than men homozygous for the deletion (6). Testosterone injections
to healthy subjects homozygous for the UGT2B17 deletion are not
detected by the expected increased T/E-ratio in urine samples, and
this has drawn great attention in the cases of anabolic steroid abuse
by male athletes (6, 7).
Several studies with focus on the urinary excretion of T and
serum T levels according to UGT2B17 genotypes in normal
men have been published (2, 5–7). However, to our knowl-
edge, no studies have investigated a possible association between
UGT2B17 genotypes and serum T levels in hypogonadal men
during T replacement therapy with long-acting testosterone
undecanoate (TU).
Our hypothesis was that the hypogonadal patients carrying the
UGT2B17 deletion may respond differently to the testosterone
treatment, and this may be reflected in changed steroid hormone
profiles, especially serum testosterone, which may prompt dose
adjustments. We also wanted to know whether UGT2B17 geno-
type should be taken into account when starting T substitution
therapy in these patients. To address this question we investigated
retrospectively the UGT2B17 genotypes in a group of hypogonadal
males treated with TU, and correlated the genotypes to their com-
prehensive hormone profiles and individual treatment regimen,
measured at several time points during therapy.
MATERIALS AND METHODS
PATIENTS AND TREATMENT
We retrospectively identified 376 men treated in our clinic with
long-acting TU (Nebido®) due to hypogonadism in the period
2005–2010. All patients, except 10, had been treated with other
testosterone products prior to TU and did not have a wash-
out phase before starting TU treatment. The patients were all
Danish citizens, predominantly Caucasian, but ethnicity was not
accounted for. The median age of the 207 men included in the
study was 39.2 years (range 15.2–71.6 years) at the treatment start.
DNA samples were available from 228 of these men and they
were genotyped for the UGT2B17 deletion polymorphism. Two
hundred and seven of these patients had initially been treated with
a standard dose of 1000 mg TU in 4 ml oily solution per injection,
and the second and third injections were given 6 and 18 weeks after
the initial. The remaining 21 patients had been given other doses
than the standard 1000 mg TU and were therefore excluded from
the final analysis. Flowchart of the patients included and excluded
in the study is depicted in Figure 1.
In our clinic the standard regimen for blood sample control
is at baseline – at the start of TU treatment, and after 2, 6 (prior
to second injection), 12, and 18 (prior to third injection) weeks.
After the first three injections, the patient’s treatment was evalu-
ated based on serum levels of total T, hemoglobin, blood pressure
as well as clinical symptoms. Subsequent evaluations were done
at control visits at 6–9 months later, where the patients were seen
in our outpatient clinic and had blood samples drawn prior to a
new injection. Changes in the individual treatment regimen were
done by adjusting the interval between the injections from 10 to
18 weeks. When the patients were considered well-adapted to ther-
apy, the subsequent injections were mainly given by the patient’s
general practitioner and follow-up at the outpatient clinic was
done approximately once a year.
FIGURE 1 | Flowchart of the patients retrospectively included in the
study.
Of the 207 patients, 130 patients had most of the blood samples
drawn according to our standard regimen and could be included
in the analysis of hormone fluctuation during the first 18 weeks of
treatment. One hundred and twenty patients had blood samples
drawn at all the standard time points, eight patients had blood
samples drawn at: 0, 2, 6, 8, and 12 weeks (missing the last con-
trol), and two patients at: 2, 6, 8, 12, and 18 weeks (missing the
baseline control). In the analysis on hormone levels prior to the
third injection we included a total of 166 patients, 122 of the
previously mentioned patients that had followed standard regi-
men as well as 44 patients who only had blood samples drawn
approximately 18 weeks after the initial injection, prior to the third
injection (Figure 1).
Of the 207 men,153 men had been treated with TU for 2–3 years
when our present analysis was performed.
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The blood sampling, clinical, and biochemical analyses were
performed as part of our standard clinical routine. The patient
record files were evaluated retrospectively and the relevant infor-
mation was extracted in unidentifiable format. The study did not
require any contact with patients, and must in accordance with
Act 2003-05-28 no. 402 be defined as a retrospective study, solely
entailing registration of specific data regarding the patient. The
study was reported to the Danish Data Protection Agency. Ref. no:
2007-41-006.
HORMONE AND HEMATOLOGICAL TESTS IN BLOOD SAMPLES
Blood samples were drawn to assess the levels of T, luteiniz-
ing hormone (LH), estradiol, and sex-hormone-binding globulin
(SHBG) as well as hemoglobin, hematocrit, Prostate Specific Anti-
gen (PSA), and cholesterol. Serum levels of T were determined
using a time-resolved fluoroimmunoassay (Delfia, Wallac, Turku,
Finland). LH and SHBG were determined using a time-resolved
immunofluorometric assay (Delfia, Wallac, Turku, Finland), and
estradiol by radioimmunoassay (Pantex, Santa Monica, CA, USA).
The intra- and inter-assay coefficient of variations (CVs) for mea-
surement of both T and SHBG were <8 and <5%, respectively.
CVs for LH were 3 and 4.5%, respectively and 7.5 and 13%
for estradiol (8) free T was calculated by the Vermeulen (FT)
formula (9).
Prostate Specific Antigen was determined by Sandwich
Electrochemiluminescence-immunoassay (ECLIA), CV max. 7%.
Cholesterol was measured enzymatically and by absorbance spec-
trophotometry, CV max. 5%. Hematocrit was measured by Reed
Blood Cell (RBC) detector counts via Hydro Dynamic Focusing
and calculated via the RBC pulse height detection method. CV
max. 2.3–2.5%. Hemoglobin was measured by chemical color reac-
tion, absorbance spectrophotometry, CV max. 1.5–2%. All tests
were performed by standard procedures at the local clinical bio-
chemistry department. These parameters were only assed prior to
the third injection.
UGT2B17 GENOTYPING
DNA was isolated from leukocytes from peripheral blood using
a semi-automatic method on the QuickGene-810 Nucleic Acid
Isolation System with the QuickGene DNA whole blood kit (Fuji-
film, Life Science Products, Tokyo, Japan). The concentration and
quality of DNA were assessed using a NanoDrop ND-1000 Spec-
trophotometer (Saveen Werner AB, Malmö, Sweden). To estab-
lish the number of copies of UGT2B17 gene, quantitative poly-
merase chain reaction (qPCR) with specific UGT2B17 primers
was performed on the Mx3000P platform (Stratagene, Cedar
Creek, TX, USA) according to the protocol described previously
in detail (5).
The three genotypes for the UGT2B17 gene polymorphism
were noted as the wild type (ins/ins), the heterozygous deletion
(ins/del), and the homozygous deletion (del/del).
STATISTICS
Kruskal–Wallis non-parametric test was performed to compare
the distribution of diagnoses as well as age and former testos-
terone treatment among the 207 patients stratified according to
the three possible genotypes.
Hormone levels as well as hemoglobin, hematocrit, total choles-
terol, and PSA were compared among the three UGT2B17 poly-
morphism groups (ins/ins, ins/del, del/del) by linear regression
models (ANOVA). Hormone and PSA levels were transformed by
the natural logarithm to obtain normal distribution of the resid-
uals. This transformation resulted in a better approximation of a
normal Gaussian distribution. Hematocrit, hemoglobin, and total
cholesterol were all normally distributed. Patients with hypogo-
nadotropic hypogonadism were excluded from any analyses of the
LH levels.
The associations between the UGT2B17 genotype and the dif-
ferent hormone levels as well as hemoglobin, hematocrit, PSA,
and total cholesterol levels were investigated at two different time
points. The first time-point constituted of the approximately first
18 weeks of TU treatment. We investigated the fluctuation of T and
estradiol during the 18 weeks,∆T levels calculated as the difference
from week 8 to 18 after initial treatment and blood samples prior
to the third injection. The second time-point was after approxi-
mately 2–3 years of individualized TU treatment. In the regression
analysis we accounted for age, previous testosterone treatment as
well as the basic diagnosis as possible confounders. Age was statis-
tically associated with the levels of free T, SHBG, and cholesterol
and therefore included in the final analyses. Previous testosterone
treatment was found to be statistically associated with LH and
therefore was also incorporated in the statistical model.
After 2–3 years of individualized TU treatment (approximately
after 9–11 injections), we compared the individual injection inter-
vals as well as the daily T dosage between men in the three
UGT2B17 genotype groups. The daily T dosage 2–3 years after
initial TU injection was calculated as the [dosage (mg)/the inter-
val (days)]. Difference between injection interval as well as daily T
doses in the three groups was tested by linear regression analysis.
SPSS version 19.0 for Windows was used to perform all
statistical analysis.
RESULTS
DISTRIBUTION OF UGT2B17 GENOTYPES
Twenty-nine of the 207 patients (14%) had a homozygous deletion
(del/del), 91 (44%) were heterozygotes (del/ins), and 87 (42%)
were wildtype for the UGT2B17 gene (ins/ins). These genotype
frequencies were in accordance to Hardy–Weinberg equilibrium
and similar to those reported previously in Caucasian populations.
There was no significant difference in age between men in the
three genotype groups.
Table 1 shows the distribution of diagnoses stratified according
to genotype. The distribution of diagnostic groups (p= 0.6) or age
(p= 0.84) did not differ between men from the three UGT2B17
groups.
RESPONSE TO TU DURING THE FIRST 1–18TH WEEKS OF TREATMENT
(FIRST–THIRD INJECTION)
Individual serum levels of T and estradiol before and during the
three TU injections according to UGT2B17 genotype are depicted
in Figures 2A,B, respectively. A large inter-individual variation in
both hormone levels was noted at the blood sampling time during
the entire 18 week period. At the blood sampling times approxi-
mately 2 weeks after the first and second injection, the serum levels
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Table 1 | Primary diagnoses stratified according to the UGT2B17 genotype.
Diagnoses ins/ins
n=87 (42.0%)
ins/del
n=91 (44.0%)
del/del
n=29 (14.0%)
Total
n=207 (100%)
Klinefelter syndrome (KS) and 46XX male 16 (39.0) 20 (48.8) 5 (12.2) 41 (100)
Primary testicular disease, excl (KS) 46 (42.6) 49 (45.4) 13 (12.0) 108 (100)
Kallmann syndrome 10 (45.5) 6 (27.3) 6 (27.3) 22 (100)
Hypo. hypogonadism (other reasons) 4 (40.0) 5 (50.0) 1 (10.0) 10 (100)
Irradiation-induced hypogonadism 3 (50.0) 3 (50.0) 0 6 (100)
Others* 8 (40.0) 8 (40.0) 4 (20.0) 20 (100)
*Injury/torsion/aplasia of the testis (n=7), Fragile X syndrome (n=1), Charge syndrome (n=1), Kennedy syndrome (n=1), Partial androgen insensitivity syndrome
(n= 3), Y-microdeletion (n=1), Liver transplant (n=1), Heart transplant (n=1), HIV (n=3), and hypogonadism induced by opiods (n=1).
FIGURE 2 | Fluctuation of the levels ofTestosterone (A) and Estradiol (B) during the first 18 weeks of treatment withTestosterone Undecanoate
stratified according to the UGT2B17 genotype. Arrows indicate the three injections.
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of T were high, with a total range from 9.3 to 69.5 nmol/l during
the first peak and from 6.7 to 66.8 nmol/l during the second peak.
There were no significant differences in serum T levels at these
peaks between the three UGT2B17 genotype groups (p> 0.05).
The increase in T values from week 8 to 18 (∆T) after ini-
tial treatment differed significantly between the three genotype
groups; men belonging to the UGT2B17 del/del group had a
smaller∆T values (median: 10.9 nmol/l) than the ins/del (median:
14.3 nmol/l) and ins/ins group (median: 18.3 nmol/l) (p= 0.001
and p= 0.003, respectively).
In accordance with T levels, estradiol levels also showed large
inter-individual variations as well as high levels at the blood
sampling times approximately 2 weeks after the first and second
injection. The serum levels of estradiol were high, with a total
range from 23 to 468 pmol/l during the first peak and from 22 to
411 pmol/l during the second peak. There were no significant dif-
ferences in serum estradiol levels at these peaks between the three
UGT2B17 genotype groups p> 0.05.
A total of 166 patients had blood samples drawn prior to
the third injection, approximately after 18 weeks of treatment.
Hormone levels, hemoglobin, hematocrit, total cholesterol, and
PSA levels stratified according to UGT2B17 genotypes as well as
statistical results are shown in Table 2.
No significant difference was detected in T levels between the
three groups (p= 0.23), neither in a simple analysis, nor in pair-
wise comparison between the individual groups. The levels of the
calculated free T showed a non-significant (p= 0.24) tendency
toward lower levels according to the number of UGT2B17 alle-
les. LH levels differed significantly between the three genotypes.
Patients homozygous for the deletion had significantly lower levels
of LH prior to the third injection compared to the heterozy-
gous and wildtype men (median; del/del: 0.5 U/l, ins/del: 3.6 U/l,
and ins/ins: 7.6 U/l), p= 0.02 and p= 0.005, respectively. SHBG,
hematocrit, hemoglobin, cholesterol as well as PSA levels did not
differ between UGT2B17 genotype.
LONG TERM (2–3 YEARS) RESPONSE TO TU TREATMENT
Of the 207 men, 153 men had been treated with TU for 2–3 years
when our present analysis was performed, with the following
UGT2B17 genotype distribution: ins/ins: n= 62 (40.5%), ins/del:
n= 70 (45.8%), del/del: n= 21 (13.7%). One patient in the ins/ins
group had his TU dosage reduced to 750 mg, the rest of the patients
were still given 1000 mg but with different injection interval if
needed. At this time-point the individual injection intervals ranged
from 10 to 18 weeks and the calculated daily TU doses from 7.94
to 14.29 mg for all 153 men. The majority of the patients had
injection intervals of 12 weeks (55.6%) or larger than 12 weeks
(13 weeks: 20.9%, 14 weeks: 2.6%, 15 weeks: 0.7%, 16 weeks: 0.7%,
and 18 weeks: 0.7%). Approximately 18.9% had injection intervals
shorter than 12 weeks with the distribution of 11 weeks: 13.7% and
10 weeks: 5.2%. The mean and median injection intervals as well as
daily testosterone dosages stratified according to UGT2B17 geno-
type are shown in Table 2. No differences in the injection interval
or daily dosage between the three genotypes were detected.
We did not find a significant association between the later
interval regime and the ∆T values during the first 18 weeks of
treatment.
DISCUSSION
In this large study of hypogonadal men, we addressed a hypothesis
that carriers of the UGT2B17 deletion polymorphism may obtain
higher serum T levels during therapy with long-acting TU, and
might need a lower T dosage than men with both alleles present.
We did not corroborate our hypothesis with regard to the nadir
levels of serum T prior to the third injection. UGT2B17 genotype
influenced serum T and LH levels only marginally. Interestingly,
we did find that men who carried a homozygous UGT2B17 dele-
tion had lower LH levels prior to the third injection and a smaller
decline in T levels from the peak levels obtained after the sec-
ond injection to the nadir levels prior to the third injection.
This could imply a slower T excretion. We speculate that despite
that the serum T levels were not significantly increased, subtle
changes in the negative feedback might have been sufficient at
the hypothalamic-pituitary level to decrease the release of LH.
However, the UGT2B17 genotype did not influence the response
to individualized TU treatment regimen, following the initial 18-
weeks fixed treatment regimen, when the daily dosage and TU
injections were adjusted.
A few previous studies have investigated the association
between UGT2B17 polymorphism and reproductive hormone
levels in serum and found no association between the baseline lev-
els of T in serum, and UGT2B17 genotype (2, 5, 10). In our own
study of Danish pubertal boys, no increase in T level or decrease
in LH were found, despite that a deletion of the UGT2B17 gene
was associated with a significantly lower level of TG in the urine
(5). One study found that Chinese young men with the del/del
genotype had significantly higher levels of both T and estradiol
compared to men carrying one or two alleles (4). To our knowl-
edge only a few studies have investigated the association of serum
levels of T after exogenous T administration (11, 12). Ekström and
co-workers found no association between UGT2B17 genotypes
and serum levels of T both baseline and 2, 4, and 15 days after a
single intramuscular exogenous T enanthate injection (11, 12).
If serum levels of T are not elevated in individuals lacking the
UGT2B17 gene – what is then the metabolic fate of T? It could
be speculated that men carrying the deletion polymorphism may
have a larger conversion of T to either dihydrotestosterone (DHT)
or estradiol. However in two studies (6, 12) no significant dif-
ferences in serum levels of DHT or urinary concentrations of
glucuronides of major final metabolites of DHT were found. Estra-
diol is rarely described in studies concerning the UGT2B17 gene,
but the previously mentioned Chinese study found higher levels
of estradiol along with T in the del/del group (4). This was not the
case in the patients examined in our current study or our former
study in pubertal boys (5).
The metabolism of TU is likely to be modulated by other factors,
in addition to UGT2B17. TU is a T ester that has to be hydrolyzed
to the active T, and factors that alter the hydrolyzation could also
influence serum T levels. It is still unknown which enzymes cat-
alyze this reaction. The phosphodiesterase 7B (PDE7B) has earlier
been linked to the hydrolysis of testosterone enanthate, and poly-
morphisms in this PDE7B gene can influence the levels of serum
T (11). Whether this polymorphism or variants in other enzymes
involved in the hydrolysis could also affect serum T levels after TU
administration remains unknown and requires further studies.
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A minor part of T is excreted as sulfate conjugates (TS), and it is
plausible that in the absence of the UGT2B17 glucuronidation, the
sulfation would be up-regulated. However previous studies have
shown that 95% of testosterone sulfate (TS) is of testicular origin
and did not find significantly higher levels of TS in accordance to
lower levels of TG (7, 13).
Another important factor that should be taken into account is a
possibility that diet or drugs may alter or inhibit the glucuronida-
tion of T. Recent studies have shown that catechins from tea
extract,phenolic compounds in red wine as well as two non-steroid
anti-inflammatory drugs (NSAIDs), diclofenac and ibuprofen,
can inhibit the glucoronidation of T in vitro (14–16). Although
NSAIDs have not shown the same effect in vivo, it remains to
be investigated whether there are other possible common dietary
substances that could have an influence on the glucuronidation
of T (17).
In this study we also analyzed T levels during the first 18 weeks
of TU treatment in a large group of hypogonadal men and noted a
wide inter- and intra-individual variation during the entire period.
TU was initially licensed in 2005 and since then several follow-up
studies of the pharmacokinetics and effects of this treatment have
been completed (18). The generally accepted treatment regimen
starts with an initial dose of 1000 mg TU followed by a second
injection 6 weeks later and hereafter every 12 weeks (19). In this
study we observed that men in the UGT2B17 del/del group expe-
rienced smaller declines in their serum T after injections. To our
knowledge this is the first time the inter-individual variation of T
throughout the initial 18 weeks of TU treatment was investigated
in correlation to UGT2B17 genotype. UGT2B17 genotype influ-
enced serum T and LH levels marginally in our hypogonadal
patients.
A former study by Moisey et al. has recommended that clini-
cians use age and body size when estimating dosing frequency in
treatment with TU (20) and the study by Ekström and co-workers
also found that serum levels of T after exogenous T administra-
tion were associated to body weight (11). We found a significant
association between age and free T but unfortunately there were
too few available weight measurements, thus we were not able to
include BMI as a confounder in any of the analysis, although this
would have been relevant.
In conclusion, we found large intra- and inter-individual vari-
ations in serum T during standard TU treatment regimen in
hypogonadal men, but noted only subtle differences in serum T
and LH in different UGT2B17 genotypes. These subtle changes
are likely due to lower T excretion rates in homozygous carriers of
the deletion, and suggest that UGT2B17 may influence the phar-
macokinetic profile of T. These observations need to be further
investigated, before UGT2B17 genotyping can be recommended
as a clinically relevant test in relation to TU treatment.
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